Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States

Lugano, Switzerland April 20, 2018 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO® (NEPA, a ... Biopharmaceuticals, Oncology, FDA Helsinn Group, AKYNZEO, fosnetupitant, palonosetron, antiemetic
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news